5/3
05:07 pm
exel
Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
Neutral
Report
Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
5/2
03:49 pm
exel
Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/2
12:41 pm
exel
Exelixis: With Patent Litigation Decision Due Soon, There Are Options [Seeking Alpha]
Low
Report
Exelixis: With Patent Litigation Decision Due Soon, There Are Options [Seeking Alpha]
5/1
02:04 pm
exel
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at TD Cowen from $25.00 to $27.00. They now have a "buy" rating on the stock.
Medium
Report
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at TD Cowen from $25.00 to $27.00. They now have a "buy" rating on the stock.
5/1
11:28 am
exel
Exelixis, Inc. (NASDAQ: EXEL) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Exelixis, Inc. (NASDAQ: EXEL) had its "outperform" rating re-affirmed by analysts at William Blair.
5/1
10:26 am
exel
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short [Yahoo! Finance]
Medium
Report
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short [Yahoo! Finance]
5/1
12:28 am
exel
Exelixis (EXEL) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Exelixis (EXEL) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
4/30
08:10 pm
exel
Exelixis (EXEL) Reports Q1 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
Low
Report
Exelixis (EXEL) Reports Q1 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
4/30
04:25 pm
exel
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
4/30
04:05 pm
exel
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
Low
Report
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
4/25
01:40 pm
exel
EXEL vs. REGN: Which Stock Is the Better Value Option? [Yahoo! Finance]
Low
Report
EXEL vs. REGN: Which Stock Is the Better Value Option? [Yahoo! Finance]
4/23
07:37 am
exel
Global Colorectal Cancer Pipeline Insights Report for 2024: An In-Depth Analysis of Clinical and Nonclinical Developments [Yahoo! Finance]
Low
Report
Global Colorectal Cancer Pipeline Insights Report for 2024: An In-Depth Analysis of Clinical and Nonclinical Developments [Yahoo! Finance]
4/18
06:23 am
exel
Pheochromocytoma Pipeline Insight Report 2024, Featuring Genentech, Exelixis, Advanced Accelerator Applications, Enterome, FUJIFILM Toyama Chemical, Ipsen, Pfizer and Astex Pharmaceuticals [Yahoo! Finance]
Low
Report
Pheochromocytoma Pipeline Insight Report 2024, Featuring Genentech, Exelixis, Advanced Accelerator Applications, Enterome, FUJIFILM Toyama Chemical, Ipsen, Pfizer and Astex Pharmaceuticals [Yahoo! Finance]
4/17
10:54 am
exel
Institutional investors in Exelixis, Inc. (NASDAQ:EXEL) lost 3.8% last week but have reaped the benefits of longer-term growth [Yahoo! Finance]
Low
Report
Institutional investors in Exelixis, Inc. (NASDAQ:EXEL) lost 3.8% last week but have reaped the benefits of longer-term growth [Yahoo! Finance]
4/16
04:05 pm
exel
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
Low
Report
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
4/16
09:15 am
exel
Global Liver Cancer Drug Market Size To Worth USD 7.6 Billion By 2033 | CAGR Of 10.90% [Yahoo! Finance]
Low
Report
Global Liver Cancer Drug Market Size To Worth USD 7.6 Billion By 2033 | CAGR Of 10.90% [Yahoo! Finance]
4/11
10:24 am
exel
Exelixis slips as Barclays downgrades on lack of catalysts [Seeking Alpha]
Low
Report
Exelixis slips as Barclays downgrades on lack of catalysts [Seeking Alpha]
4/11
08:00 am
exel
Exelixis, Inc. (NASDAQ: EXEL) was downgraded by analysts at Barclays PLC from an "overweight" rating to an "equal weight" rating. They now have a $25.00 price target on the stock.
Low
Report
Exelixis, Inc. (NASDAQ: EXEL) was downgraded by analysts at Barclays PLC from an "overweight" rating to an "equal weight" rating. They now have a $25.00 price target on the stock.
4/10
11:20 am
exel
Exelixis, Inc. (NASDAQ: EXEL) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $27.00 price target on the stock.
Low
Report
Exelixis, Inc. (NASDAQ: EXEL) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $27.00 price target on the stock.
4/9
01:00 pm
exel
EXEL or REGN: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
Low
Report
EXEL or REGN: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
3/28
03:03 pm
exel
Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024 [Seeking Alpha]
Low
Report
Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024 [Seeking Alpha]
3/25
01:26 pm
exel
2 More Potential Biotech Buyout Targets [Seeking Alpha]
Low
Report
2 More Potential Biotech Buyout Targets [Seeking Alpha]
3/21
08:46 am
exel
Exelixis, Inc.'s (NASDAQ:EXEL) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue? [Yahoo! Finance]
Low
Report
Exelixis, Inc.'s (NASDAQ:EXEL) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue? [Yahoo! Finance]
3/19
06:40 pm
exel
Exelixis, Inc. (NASDAQ: EXEL) was upgraded by analysts at TheStreet from a "c+" rating to a "b-" rating.
Low
Report
Exelixis, Inc. (NASDAQ: EXEL) was upgraded by analysts at TheStreet from a "c+" rating to a "b-" rating.
3/13
02:28 pm
exel
Prostate Cancer - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033 [Yahoo! Finance]
Low
Report
Prostate Cancer - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033 [Yahoo! Finance]